213 related articles for article (PubMed ID: 37880703)
1. Immunological role and clinical prognostic significance of P2RY6 in lung adenocarcinoma: a multi-omics studies and single-cell sequencing analysis.
Wu H; Dong X
World J Surg Oncol; 2023 Oct; 21(1):341. PubMed ID: 37880703
[TBL] [Abstract][Full Text] [Related]
2. Pyrimidinergic receptor P2Y6 expression is elevated in lung adenocarcinoma and is associated with poor prognosis.
Wang X; Zhao B; Ren D; Hu X; Qiao J; Zhang D; Zhang Y; Pan Y; Fan Y; Liu L; Wang X; Ma H; Jia X; Song S; Zhao C; Liu J; Wang L
Cancer Biomark; 2023; 38(2):191-201. PubMed ID: 37545227
[TBL] [Abstract][Full Text] [Related]
3. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
4. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
5. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics immune regulatory mechanisms in lung adenocarcinoma metastasis and survival time.
Liu D; Yao L; Ding X; Zhou H
Comput Biol Med; 2023 Sep; 164():107333. PubMed ID: 37586202
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13.
Wang J; Shi W; Miao Y; Gan J; Guan Q; Ran J
Bioengineered; 2021 Dec; 12(1):6286-6304. PubMed ID: 34494914
[TBL] [Abstract][Full Text] [Related]
10. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
Liu W; Du Q; Mei T; Wang J; Huang D; Qin T
BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752
[TBL] [Abstract][Full Text] [Related]
12. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
15. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.
Yang W; Chen K; Yu Q; Liao R; He H; Peng Y; Yang Z; Zhang X
Cancer Med; 2023 Jul; 12(13):14820-14832. PubMed ID: 37162299
[TBL] [Abstract][Full Text] [Related]
16. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
17. Integrative single-cell analysis of LUAD: elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells.
Zhang H; Zhang P; Lin X; Tan L; Wang Y; Jia X; Wang K; Li X; Sun D
Front Immunol; 2024; 15():1366096. PubMed ID: 38596689
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
19. Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.
Fan T; Zhu M; Wang L; Liu Y; Tian H; Zheng Y; Tan F; Sun N; Li C; He J
Aging (Albany NY); 2020 Dec; 13(2):2397-2417. PubMed ID: 33318300
[TBL] [Abstract][Full Text] [Related]
20. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]